International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 parental study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507180-19-00

Acronym

LTS17704

Enrollment

Registered

2024-04-15

Start date

2023-04-05

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Number of participants with treatment-emergent adverse events

Interventions

DRUGMONTELUKAST

DRUGImnovid 2 mg hard capsules

DRUGZelvina 10 mg hard capsules

DRUGDIPHENHYDRAMINE

DRUGZelvina 5 mg hard capsules

DRUGPARACETAMOL

DRUGZelvina 20 mg hard capsules

DRUGJAMP Pomalidomide

DRUGMETHYLPREDNISOLONE

DRUGLIBTAYO 350 mg concentrate for solution for infusion.

DRUGRevlimid 20 mg hard capsules

DRUGSARCLISA 20mg/mL concentrate for solution for infusion.

DRUGRevlimid 25 mg hard capsules

DRUGImnovid 3 mg hard capsules

DRUGPomalidomide Adalvo 1 mg hard capsules

DRUGRevlimid 10 mg hard capsules

DRUGRevlimid 15 mg hard capsules

DRUGDEXAMETHASONE BASE

DRUGRevlimid 5 mg hard capsules

DRUGPomalidomide Adalvo 4 mg hard capsules

DRUGImnovid 1 mg hard capsules

DRUGKyprolis 60 mg powder for solution for infusion

DRUGIsatuximab

DRUGDexamethason 4 mg JENAPHARM®

DRUGPomalidomide Adalvo 3 mg hard capsules

DRUGPomalidomide Adalvo 2 mg hard capsules

DRUGImnovid 4 mg hard capsules

DRUGDexamethason 8 mg JENAPHARM®

DRUGZelvina 15 mg hard capsules

DRUGZelvina 25 mg hard capsules

DRUGDexaGalen® 8 mg injekt Injektionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants with treatment-emergent adverse events	—

Countries

Czechia, Finland, France, Greece, Italy, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026